Nasdaq

ProPhase Labs Inc. Validates BE-Smart™ Diagnostic Test for Esophageal Disease with Over 95% Success Rate

ProPhase Labs announces BE-Smart's validation for esophageal disease diagnostics, achieving over 95% success in detecting critical biomarkers. ProPhase Labs Inc. announced the successful validation of ...
Seeking Alpha

ProPhase Labs Announces Successful Study Demonstrating Performance of BE-Smart™ Test in Detecting Esophageal Cancer

BE-Smart represents a significant advance in diagnosis and management of Esophageal disease that affects an estimated 60 million people in the United States Study shows >95% success rate, validating ...
Nasdaq

ProPhase Labs Inc. Establishes Clinical Science Advisory Board to Advance BE-SmartTM Test for Esophageal Disease Detection

ProPhase Labs Inc. has announced the formation of a Clinical Science Advisory Board to support the commercialization of its BE-Smart™ molecular test for esophageal disease, aimed at early detection ...